论文部分内容阅读
得到完全缓解的急性髓细胞白血病(AML)患者中80%由于存留的微小残留病(MRD)而复发,存活率仅有30%~40%,因此由免疫系统监视清除MRD是白血病免疫治疗的主要目标。树突状细胞(DC)是重要的抗原递呈细胞(APC),能在体内外直接激活初始T细胞及细胞毒性T细胞(CTL)的
80% of patients with completely remitted acute myeloid leukemia (AML) relapse due to residual minimal residual disease (MRD) and have a survival rate of only 30% to 40%. Therefore, clearance of MRD by the immune system is the major leukemia immunotherapy aims. Dendritic cells (DCs) are important antigen presenting cells (APCs) that directly activate naive T cells and cytotoxic T cells (CTLs) both in vitro and in vivo